1. Home
  2. ECO vs MESO Comparison

ECO vs MESO Comparison

Compare ECO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Okeanis Eco Tankers Corp.

ECO

Okeanis Eco Tankers Corp.

HOLD

Current Price

$55.45

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.00

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECO
MESO
Founded
2018
2004
Country
Greece
Australia
Employees
N/A
81
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
ECO
MESO
Price
$55.45
$16.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$42.00
N/A
AVG Volume (30 Days)
359.3K
187.2K
Earning Date
05-13-2026
02-26-2026
Dividend Yield
6.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.07
$629.74
Revenue Next Year
N/A
$30.65
P/E Ratio
$18.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.27
$9.88
52 Week High
$57.29
$21.50

Technical Indicators

Market Signals
Indicator
ECO
MESO
Relative Strength Index (RSI) 64.52 55.57
Support Level $48.57 $15.62
Resistance Level $57.29 $16.37
Average True Range (ATR) 2.07 0.38
MACD 0.32 0.03
Stochastic Oscillator 83.98 47.49

Price Performance

Historical Comparison
ECO
MESO

About ECO Okeanis Eco Tankers Corp.

Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: